The recommendations for hospitalized children with MIS-C include:
- Use of corticosteroids in addition to supportive care (rather than either intravenous immunoglobulin plus supportive care, or supportive care alone), for hospitalized children aged 0-18 years old who meet a standard case definition for MIS-C.
- Use of corticosteroids in addition to standard of care for hospitalized children aged 0-18 years who meet both a standard case definition for MIS-C and diagnostic criteria for Kawasaki disease.
The updated guidance is part of the WHO’s COVID-19 resource, Clinical management: living guidance, which contains the organization’s most up-to-date recommendations for the clinical management of COVID-19 patients.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
